Journal
LEUKEMIA
Volume 21, Issue 10, Pages 2128-2136Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.leu.2404885
Keywords
acute lymphoblastic leukemia; loss of heterozygosity; single nucleotide polymorphisms; microarrays
Categories
Funding
- NCI NIH HHS [T32-CA070089, CA 36401, CA 78224, CA21765, CA 51001] Funding Source: Medline
- NIGMS NIH HHS [U01 GM61393, U01GM61374] Funding Source: Medline
Ask authors/readers for more resources
The genetic risk factors for etoposide-induced leukemia with MLL translocations remain largely unknown. To identify genetic risk factors for and novel characteristics of secondary leukemia, we profiled 116 204 single nucleotide polymorphisms ( SNPs) in germline and paired leukemic cell DNA from 13 secondary leukemia/myelodysplasia cases and germline DNA from 13 matched and 156 unmatched controls, all with acute lymphoblastic leukemia treated with etoposide. We analyzed global gene expression from a partially overlapping cohort. No single locus was altered in most cases. We discovered 81 regions of loss of heterozygosity (LOH) in leukemic blasts and 309 SNPs whose allele frequencies differed in cases vs controls. Candidate genes were prioritized on the basis of genes whose SNPs or expression differentiated cases from controls or showed LOH or copy number change in germline vs paired blast DNA from the13 cases. Three biological pathways were altered: adhesion, Wnt signaling and regulation of actin. Validation experiments using a genome scan for etoposide-induced leukemogenic MLL chimeric fusions in 15 HapMap cell lines also implicated genes involved in adhesion, a process linked to de novo leukemogenesis. Independent clinical epidemiologic and in vitro genome-wide approaches converged to identify novel pathways that may contribute to therapyinduced leukemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available